CNS Response (MYND) Earning Somewhat Positive Media Coverage, Study Finds
Media headlines about CNS Response (NASDAQ:MYND) have trended somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CNS Response earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.5500554421226 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
- Texas high school football players kicked off team for protesting during national anthem (whio.com)
- Brain Tumor Diagnosis and Treatments Market: Regional & Competitive Analysis (digitaljournal.com)
- Brain Tumor Diagnosis and Treatments Market Research Report by Geographical Analysis and Forecast to 2024 (sbwire.com)
- California candidate’s phone texts creeping out some voters (scpr.org)
- Bavencio (avelumab) Approved for Merkel Cell Carcinoma in Japan (consumerelectronicsnet.com)
Separately, Maxim Group reissued a “buy” rating and set a $18.00 target price on shares of CNS Response in a research report on Tuesday, September 26th.
CNS Response (NASDAQ:MYND) traded down 5.51% during midday trading on Monday, hitting $3.60. 27,867 shares of the stock were exchanged. The stock’s market cap is $15.26 million. The company’s 50 day moving average is $3.84 and its 200-day moving average is $5.76. CNS Response has a 1-year low of $3.10 and a 1-year high of $10.00.
CNS Response (NASDAQ:MYND) last posted its quarterly earnings results on Monday, August 14th. The company reported ($0.62) earnings per share (EPS) for the quarter. The business had revenue of $0.04 million for the quarter.
In related news, Director John Pappajohn purchased 10,000 shares of CNS Response stock in a transaction that occurred on Tuesday, July 18th. The shares were acquired at an average cost of $4.47 per share, for a total transaction of $44,700.00. Following the transaction, the director now directly owns 511,290 shares in the company, valued at $2,285,466.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have purchased a total of 35,000 shares of company stock valued at $142,150 over the last 90 days. 17.81% of the stock is currently owned by company insiders.
About CNS Response
MYnd Analytics, Inc, formerly CNS Response, Inc, is a predictive analytics company. The Company has developed a decision support tool to help physicians reduce trial and error treatment in mental health, and provide personalized care to patients. The Company provides objective clinical decision support to mental healthcare providers for the personalized treatment of behavioral disorders, including depression, anxiety, bipolar disorder, post-traumatic stress disorder (PTSD) and other non-psychotic disorders.
Receive News & Stock Ratings for CNS Response Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Response Inc. and related stocks with our FREE daily email newsletter.